Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body. Benign prostatic hyperplasia (BPH) is an enlarged prostate, which increases the size of the prostate gland. As the prostate gets enlarged, it may squeeze or partly block the urethra, resulting in significantly blocking urine flow. BPH is normal in the aging process of a male, caused by changes in hormone balance and cell-growth.
The increasing demand for Benign Prostatic Hyperplasia (BPH) Drugs drives the market. Three factors contributing to the growth of the global benign prostatic hyperplasia drugs market are growing geriatric male population, strong r&d and growing demand for alpha-blockers. The evolution of alpha-blockers therapy for BPH has focused on improving convenience and tolerability. Reversing signs and symptoms or preventing progression of the disease are the indications of treating BPH. Alpha-blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Additionally, one driver in market is growing geriatric male population. The presence of a large population with BPH symptoms is expected to drive the market growth. The risk of BPH increases exponentially with the rise in the age of an individual. Approximately, 80% of men who reach 60 years and above have mild to strong symptoms of BPH. This disorder affects one in 38 individuals in the age group of 40-59 years; however, in the age group of 60-69 years, it affects one in 14 individuals. The BPH drugs market in the Americas accounted for the majority market share during 2016 and the market in this region is likely to experience a high growth rate during the estimated period. Factors such as the growing demand for urology-related disorders and the increasing rate of geriatric men population, will stimulate the demand for BPH drugs and fuel the market’s growth.
This report elaborates on the current development of the Benign Prostatic Hyperplasia (BPH) Drugs industry thoroughly based on the international market dynamics and China's market situation.
For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.
Secondly, this report lists the major players in the industry, displaying their market positions along with the strengths and weaknesses of their products, picturing the current competitive situation of the whole market.
Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.
Please note that the figures and tables shown in the sample are just for the purpose of demonstration, which may differ from those in the final report.
Competitive Landscape:
Endo Pharmaceuticals
Astellas Pharma
Bayer HealthCare
GlaxoSmithKline
Bristol-Myers Squibb
Sanofi
Foresee Pharmaceuticals
ADC Therapeutics
Eli Lilly
Valeant Pharmaceuticals
Region:
-
China
-
North America
-
Europe
-
APAC
-
Latin America, Middle East and Africa
Type:
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
5-Alpha-Reductase Inhibitors
Application:
Men
Women
Table of Content
Chapter 1 Industry Overview & Development Status in Global and China Market
-
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Overview
-
1.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Scope and Market Segments
-
1.1.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Characteristics
-
1.1.3 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
1.1.4 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Production Value and Growth Rate (2017-2028)
-
1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate by Type (2017-2028)
-
1.2.1 Alpha-Blocker
-
1.2.2 Phosphodiesterase Type-5 Inhibitors
-
1.2.3 5-Alpha-Reductase Inhibitors
-
1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate by Application (2017-2028)
-
1.3.1 Men
-
1.3.2 Women
-
1.4 Market Analysis by Region
-
1.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
1.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
1.4.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
1.4.4 Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
1.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
1.6 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Price, Sales Value (2017-2028)
-
1.6.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Price, Sales Value (2017-2028)
Chapter 2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Trends and Competitive Landscape
-
2.1 Market Trends and Dynamics
-
2.1.1 Challenges and Restraints
-
2.1.2 Opportunities and Potentialities
-
2.1.3 Mergers and Acquisitions
-
2.2 Competitive Landscape
-
2.2.1 Market Concentration Rate Analysis
-
2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Porter's Five Forces Model Analysis
-
2.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry PEST Analysis
-
2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis
-
2.3.1 Raw Material Supplies
-
2.3.2 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Market Analysis
-
2.3.3 Upstream and Downstream Impacts on Benign Prostatic Hyperplasia (BPH) Drugs Industry
Chapter 3 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Manufacturer
-
3.1 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Market Share, by Manufacturer (2021&2022)
-
3.1.1 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Manufacturer (2021&2022)
-
3.1.2 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value, by Manufacturer (2021&2022)
-
3.1.3 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market Share, by Manufacturer (2021&2022)
-
3.2 SWOT Analysis on Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market Top 3 Players
Chapter 4 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type (2017-2028)
-
4.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Trend, by Type
-
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value, Market Share and Price Trend, by Type
-
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share, by Type (2017-2028)
-
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Market Share, by Type (2017-2028)
-
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trend, by Type (2017-2028)
-
4.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value, Market Share and Price Trend, by Type
-
4.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share, by Type (2017-2028)
-
4.3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Market Share, by Type (2017-2028)
-
4.3.3 China Benign Prostatic Hyperplasia (BPH) Drugs Price Trend, by Type (2017-2028)
Chapter 5 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application (2017-2028)
-
5.1 Downstream Market Overview
-
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Market Share, by Application
-
5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share, by Application (2017-2028)
-
5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Market Share, by Application (2017-2028)
-
5.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Market Share, by Application
-
5.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Market Share, by Application (2017-2028)
-
5.3.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Market Share, by Application (2017-2028)
Chapter 6 Global Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export, by Region (2017-2022)
-
6.1 China Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
6.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
6.4 APAC Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
6.5 Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
Chapter 7 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis
-
7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type
-
7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application
-
7.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast, by Country
-
7.3.1 United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
7.3.2 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
7.3.3 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 8 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis
-
8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type
-
8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application
-
8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast, by Country
-
8.3.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.2 UK Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.3 France Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.4 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.5 Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.6 Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.7 Belgium Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.8 Poland Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.9 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
8.3.10 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 9 APAC Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis
-
9.1 APAC Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type
-
9.2 APAC Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application
-
9.3 APAC Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast, by Country
-
9.3.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.3 Australia and New Zealand Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.4 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.5 ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
9.3.6 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 10 Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis
-
10.1 Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market, by Type
-
10.2 Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market, by Application
-
10.3 Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast, by Country
-
10.3.1 GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.3 Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.4 South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
-
10.3.5 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)
Chapter 11 Global and China Benign Prostatic Hyperplasia (BPH) Drugs Company Profiles
-
11.1 Endo Pharmaceuticals
-
11.1.1 Endo Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.1.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.1.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.2 Astellas Pharma
-
11.2.1 Astellas Pharma Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.2.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.2.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.3 Bayer HealthCare
-
11.3.1 Bayer HealthCare Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.3.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.3.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.4 GlaxoSmithKline
-
11.4.1 GlaxoSmithKline Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.4.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.4.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.5 Bristol-Myers Squibb
-
11.5.1 Bristol-Myers Squibb Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.5.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.5.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.6 Sanofi
-
11.6.1 Sanofi Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.6.2 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.6.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.7 Foresee Pharmaceuticals
-
11.7.1 Foresee Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.7.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.7.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.8 ADC Therapeutics
-
11.8.1 ADC Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.8.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.8.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.9 Eli Lilly
-
11.9.1 Eli Lilly Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.9.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.9.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
11.10 Valeant Pharmaceuticals
-
11.10.1 Valeant Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
11.10.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Product Profiles, Application and Specification
-
11.10.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
Chapter 12 Benign Prostatic Hyperplasia (BPH) Drugs Industry Investment Prospect and Risk Assessment
-
12.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Investment Prospect Assessment
-
12.1.1 Investment Opportunities in Segmented Markets
-
12.1.2 Investment Opportunities in Regional Markets
-
12.1.3 Investment Opportunities in Subdivided Industries
-
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Investment Risk Assessment
-
12.2.1 Competitive Risk Analysis
-
12.2.2 Technology Risk Analysis
-
12.2.3 Policies and Enterprise System Risk Analysis
List of Tables and Figures
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Production Value and Growth Rate (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production Value and Growth Rate (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Alpha-Blocker (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Phosphodiesterase Type-5 Inhibitors (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of 5-Alpha-Reductase Inhibitors (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Men (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and Growth Rate of Women (2017-2028)
-
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
Figure Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Consumption Market Size and Growth Rate (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Price, Sales Value (2017-2028)
-
Figure Porter's Five Forces Model Analysis
-
Figure Industry PEST Analysis
-
Table Global and China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Manufacturer (2021&2022)
-
Table Global and China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value, by Manufacturer (2021&2022)
-
Table Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market Share, by Manufacturer (2021&2022)
-
Figure Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market Share, by Manufacturer in 2021
-
Figure Global and China Benign Prostatic Hyperplasia (BPH) Drugs Market Share, by Manufacturer in 2022
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Type (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value, by Type (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share, by Type (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Price Trend, by Type (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Type (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value, by Type (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share, by Type (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Price Trend, by Type (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Application (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value, by Application (2017-2028)
-
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share, by Application (2017-2028)
-
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share, by Application (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Application (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value, by Application (2017-2028)
-
Table China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share, by Application (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share, by Application (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
Figure Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Production, Import, Consumption and Export (2017-2022)
-
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Type (2017-2028)
-
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Application (2017-2028)
-
Table North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure United States Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Type (2017-2028)
-
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Application (2017-2028)
-
Table Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure UK Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Belgium Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Belgium Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Poland Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Poland Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Type (2017-2028)
-
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Application (2017-2028)
-
Table APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure APAC Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Australia and New Zealand Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Australia and New Zealand Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure ASEAN Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Table Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Type (2017-2028)
-
Table Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Figure Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Type (2017-2028)
-
Table Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, by Application (2017-2028)
-
Table Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure Latin America, Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share, by Application (2017-2028)
-
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Nigeria Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure South Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume and Growth Rate (2017-2028)
-
Figure Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value and Growth Rate (2017-2028)
-
Table Endo Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Endo Pharmaceuticals Product Profiles, Application and Specification
-
Table Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Astellas Pharma Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Astellas Pharma Product Profiles, Application and Specification
-
Table Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Bayer HealthCare Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Bayer HealthCare Product Profiles, Application and Specification
-
Table Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table GlaxoSmithKline Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table GlaxoSmithKline Product Profiles, Application and Specification
-
Table GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Bristol-Myers Squibb Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Bristol-Myers Squibb Product Profiles, Application and Specification
-
Table Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Sanofi Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Sanofi Product Profiles, Application and Specification
-
Table Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Foresee Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Foresee Pharmaceuticals Product Profiles, Application and Specification
-
Table Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table ADC Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table ADC Therapeutics Product Profiles, Application and Specification
-
Table ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Eli Lilly Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Eli Lilly Product Profiles, Application and Specification
-
Table Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
Table Valeant Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position
-
Table Valeant Pharmaceuticals Product Profiles, Application and Specification
-
Table Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)
-
